Payment overview · 2025
General Payments
$7,927.31
109 reported records · 18 companies
Healthcare provider profile · identity verified
Sima Muster
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1508890740
Verified facts
What the public records show
CMS Open Payments records show Sima Muster received $7,927.31 in general payments during 2025 across 109 reported records.
ABBVIE INC. accounted for 75.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Linzess, Otezla, Ozempic, Prolia, Trelegy Ellipta, Ubrelvy, Verquvo, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 440 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 514 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 514 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,989.13 | 75.5% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.12 | 4.2% | 14 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $281.06 | 3.5% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.36 | 2.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $191.88 | 2.4% | 8 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $190.31 | 2.4% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.40 | 2.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $122.23 | 1.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.92 | 1.1% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $78.53 | 1.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.84 | 0.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $48.99 | 0.6% | 3 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $46.21 | 0.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.23 | 0.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.11 | 0.3% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $25.47 | 0.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.72 | 0.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,875.00 | 3 |
| Food and Beverage | $2,977.31 | 105 |
| Travel and Lodging | $75.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $5,491.45 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $237.54 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $199.02 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $191.88 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $190.31 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $178.40 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $172.85 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.96 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.27 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $144.47 | 7 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $132.14 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $127.40 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127.40 | 6 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $95.49 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $82.92 | 3 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $82.92 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $78.53 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.96 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.96 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $57.15 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $55.27 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $54.84 | 3 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $53.43 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $46.21 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 167 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 514 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 120 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 440 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 159 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 82 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 244 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
167 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
440 | 72 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
286 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
514 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
514 | 61 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 855 | 193 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 748 | 149 |
| Metoprolol Succinate | Metoprolol Succinate | 723 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 130 |
| Vascepa | Icosapent Ethyl | 535 | 80 |
| Eliquis | Apixaban | 514 | 61 |
| Linzess | Linaclotide | 440 | 72 |
| Omeprazole | Omeprazole | 440 | 87 |
| Diclofenac Sodium | Diclofenac Sodium | 417 | 93 |
| Allopurinol | Allopurinol | 409 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 408 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 367 | 90 |
| Icosapent Ethyl | Icosapent Ethyl | 332 | 58 |
| Losartan Potassium | Losartan Potassium | 311 | 74 |
| Metformin Hcl | Metformin Hcl | 307 | 68 |
| Famotidine | Famotidine | 302 | 67 |
| Synthroid | Levothyroxine Sodium | 286 | 48 |
| Furosemide | Furosemide | 276 | 57 |
| Zenpep | Lipase/Protease/Amylase | 244 | 37 |
| Simvastatin | Simvastatin | 234 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 228 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 187 | 37 |
| Gabapentin | Gabapentin | 182 | 55 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 182 | 43 |
| Carvedilol | Carvedilol | 180 | 37 |
| Meloxicam | Meloxicam | 176 | 58 |
| Ezetimibe | Ezetimibe | 173 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 169 | 42 |
| Creon | Lipase/Protease/Amylase | 167 | 34 |
| Ranolazine Er | Ranolazine | 160 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 159 | 43 |
| Myrbetriq | Mirabegron | 154 | 28 |
| Ketoconazole | Ketoconazole | 153 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 37 |
| Finasteride | Finasteride | 144 | 23 |
| Spironolactone | Spironolactone | 144 | 26 |
| Glimepiride | Glimepiride | 141 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 140 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 137 | 31 |
| Alendronate Sodium | Alendronate Sodium | 131 | 24 |
| Lisinopril | Lisinopril | 130 | 27 |
| Donepezil Hcl | Donepezil Hcl | 127 | 22 |
| Clonidine Hcl | Clonidine Hcl | 125 | 38 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 123 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 121 | 26 |
| Farxiga | Dapagliflozin Propanediol | 120 | 22 |
| Atenolol | Atenolol | 112 | 20 |
| Hydrocortisone | Hydrocortisone | 112 | 36 |
| Meclizine Hcl | Meclizine Hcl | 112 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 112 | 23 |
| Januvia | Sitagliptin Phosphate | 109 | 18 |
| Jardiance | Empagliflozin | 108 | 24 |
| Colchicine | Colchicine | 105 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 31 |
| Dutasteride | Dutasteride | 87 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 18 |
| Trulicity | Dulaglutide | 82 | 13 |
| Vraylar | Cariprazine Hcl | 82 | 14 |
| Ammonium Lactate | Ammonium Lactate | 81 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 81 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 72 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 75 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 14 |
| Montelukast Sodium | Montelukast Sodium | 75 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 14 |
| Ibuprofen | Ibuprofen | 73 | 33 |
| Azithromycin | Azithromycin | 72 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 18 |
| Mupirocin | Mupirocin | 67 | 26 |
| Tradjenta | Linagliptin | 66 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 64 | 16 |
| Lidocaine | Lidocaine | 63 | 16 |
| Dexilant | Dexlansoprazole | 62 | 13 |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 16 |
| Jentadueto | Linagliptin/Metformin Hcl | 60 | suppressed |
| Torsemide | Torsemide | 60 | 12 |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Levofloxacin | Levofloxacin | 59 | 49 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 25 |
| Repaglinide | Repaglinide | 57 | suppressed |
| Loperamide | Loperamide Hcl | 55 | 17 |
| Valsartan | Valsartan | 54 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 52 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 52 | suppressed |
| Ozempic | Semaglutide | 50 | 11 |
| Cilostazol | Cilostazol | 49 | suppressed |
| Lansoprazole | Lansoprazole | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 46 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 45 | 13 |
| Ubrelvy | Ubrogepant | 43 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 41 | 12 |
| Potassium Chloride | Potassium Chloride | 41 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Procto-Med Hc | Hydrocortisone | 38 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 21 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Nystatin | Nystatin | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 17 |
| Prolia | Denosumab | 31 | 17 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Ibu | Ibuprofen | 28 | suppressed |
| Prednisone | Prednisone | 28 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 27 | suppressed |
| Verquvo | Vericiguat | 27 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Desloratadine | Desloratadine | 25 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Ssd | Silver Sulfadiazine | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Silodosin | Silodosin | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Bystolic | Nebivolol Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 18 |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Glipizide | Glipizide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Otezla | Apremilast | 14 | suppressed |
| Relpax | Eletriptan Hydrobromide | 14 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Plavix | Clopidogrel Bisulfate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,927.31 · 109 records | ABBVIE INC. | Andembry, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, CREON, ELIQUIS, EVENITY, FARXIGA, Fabhalta, GEMTESA, Grastek, Haegarda, IBSRELA, Kcentra, LINZESS, LYBALVI, NURTEC ODT, ORLADEYO, OTEZLA, Odactra, Ozempic, PROLIA, QULIPTA, REPATHA, Ragwitek, Symbravo, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, VYNDAQEL, Vanrafia, ZAVZPRET, ZENPEP | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error